Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
13.08
+0.23 (1.79%)
At close: Dec 20, 2024, 4:00 PM
12.52
-0.56 (-4.29%)
After-hours: Dec 20, 2024, 6:38 PM EST
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $12.50M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $16.00M.
Revenue (ttm)
$16.00M
Revenue Growth
n/a
P/S Ratio
67.13
Revenue / Employee
$86,957
Employees
184
Market Cap
1.12B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tilray Brands | 812.04M |
Innoviva | 352.75M |
CareDx | 312.78M |
Ardelyx | 251.85M |
Weave Communications | 195.84M |
Establishment Labs Holdings | 153.07M |
BioLife Solutions | 146.96M |
ARS Pharmaceuticals | 2.57M |
SNDX News
- 12 days ago - Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial - PRNewsWire
- 14 days ago - Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting - PRNewsWire
- 18 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 24 days ago - Syndax Announces Participation at the Citi 2024 Global Healthcare Conference - PRNewsWire
- 5 weeks ago - US FDA approves Syndax's blood cancer drug - Reuters
- 5 weeks ago - Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation - PRNewsWire
- 5 weeks ago - Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity - Seeking Alpha
- 5 weeks ago - Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib - PRNewsWire